Marín Pozo J F, Nacle López I, Zambora Ardoy M A, Vílchez Medina T, Millán García R, Mora Mora M A
Servicio de Farmacia, Hospital General de Especialidades Ciudad de Jaén, España.
Nutr Hosp. 1998 Mar-Apr;13(2):99-107.
The present work aims to study the use of enteral nutrition (EN) products during the period between October 1996 and January 1997, in a general hospital with a nutrition unit. The EN expenditure ascended to 3,343,475 Pesetas, with the supplements representing the greatest cost percentage (39.1%). An indication-prescription study was carried out by reviewing 120 clinical histories of patients who had received EN during that period. The patients originated in different departments of the hospital, excluding the ICU, chronic patients, pediatrics, and palliative care. Data regarding sex, age, diagnosis, diet used, calories/day given, route of administration, and selection criterion for the diet were analysed. The average age of the patients was 64.59 years. The most common diagnoses were solid tumors (32.5% of the cases), followed by cerebrovascular accidents (16.7% of the cases). The most commonly used EN preparation was the Pentadrink hypercaloric diet (36.7% of the cases), followed by the standard diet (25.8%). The route of administration used most frequently was the oral route in 63.3% of the cases. The calories/day given varied per diet, with this being 886 cal for the hypercaloric diet, and 1,839 cal for the standard diet. Among the criteria for selecting an EN diet 50% of the patients had abnormal protein metabolism and a normal digestive capacity with slight or moderate stress, 12.5% were diabetic; and the remainder presented other criteria that influenced the choice for a specific type of EN diet. From the analysis of the results it is clear that Pentadrink is used as a supplement, and that there are patients with a sometimes insufficient caloric supply.
本研究旨在调查1996年10月至1997年1月期间,在一家设有营养科的综合医院中肠内营养(EN)产品的使用情况。肠内营养支出达3,343,475比塞塔,其中补充剂的费用占比最大(39.1%)。通过回顾120例在此期间接受肠内营养治疗的患者的临床病历,开展了一项适应证-处方研究。患者来自医院的不同科室,不包括重症监护病房、慢性病患者、儿科患者和姑息治疗患者。分析了患者的性别、年龄、诊断结果、所用饮食、每日热量供给、给药途径以及饮食选择标准等数据。患者的平均年龄为64.59岁。最常见的诊断为实体瘤(占病例的32.5%),其次是脑血管意外(占病例的16.7%)。最常用的肠内营养制剂是Pentadrink高热量饮食(占病例的36.7%),其次是标准饮食(占25.8%)。最常用的给药途径是口服,占病例的63.3%。不同饮食的每日热量供给有所不同,高热量饮食为886千卡,标准饮食为1,839千卡。在选择肠内营养饮食的标准中,50%的患者蛋白质代谢异常但消化能力正常,处于轻度或中度应激状态;12.5%的患者患有糖尿病;其余患者则有其他影响特定类型肠内营养饮食选择的标准。从结果分析可以明显看出,Pentadrink被用作补充剂,且存在热量供应有时不足的患者。